Lantheus (NASDAQ: LNTH) holders to vote on cash buyout with potential bonus payout
Lantheus (LNTH) stockholders will vote on a $102.50 cash-plus-CVR sale to Curium, delisting LNTH from Nasdaq. Each share gets $102.50 cash plus a CVR for up to $12.00 more if milestones are met by 2031. The board recommends approval, requiring a majority vote. The deal, valued at $7.45 billion, needs stockholder and regulatory approvals.
How this was made
The 30-second read
Why it matters
The deal provides a $102.50 cash floor per share plus up to $12.00 contingent cash, likely driving the stock toward that level before delisting.
Market read
A material M&A transaction with a clear cash component, affecting LNTH shareholders and potentially setting a precedent for CVR‑structured deals in the sector.
What to watch
Regulatory clearance risk and potential appraisal litigation could delay or derail the transaction.
Background
Lantheus Holdings announced a definitive proxy for a cash‑plus‑contingent value right merger with Curium US Holdings, with a record date of Sep 1 and a virtual meeting on Oct 14.
Ticker impact
Shareholders will vote on a $102.50 cash‑plus‑CVR merger with Curium, potentially taking LNTH private and delisting it.
Share price likely to rise toward the $102.50 cash component ahead of the vote, then cease trading post‑close.
The merger is a material $7.45 bn transaction with a clear cash floor; market participants will price in the deal premium and CVR upside.
Market effects
Consolidation in the nuclear medicine imaging sector may pressure peers' valuations.
US biotech and medical‑device markets see a notable M&A event.
Limited to the niche radiopharmaceutical space; broader market impact minimal.
Counterpoint
If the CVR milestones are not met, total consideration could fall short of market expectations, hurting long‑term value.
Key entities
- CompanyLantheus Holdings, Inc.
Target of the merger, currently listed on Nasdaq (LNTH).
- CompanyCurium US Holdings LLC
Acquiring parent, will take LNTH private.
